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abstract

To address health disparities faced by Black patients with cancer, it is critical that researchers conducting
cancer clinical trials (CCTs) equitably recruit and retain Black participants, develop strategies toward this aim,
and document associated outcomes. This narrative scoping literature review, as part of a larger study, aimed to
identify, describe, and categorize strategies and interventions intended to improve the recruitment and retention
of Black participants with breast, lung, prostate, colorectal, or multiple myeloma cancer into CCTs. We conducted comprehensive searches in PubMed, Embase, Cochrane Library, PsycInfo, CINAHL, Scopus, and Web
of Science with three main concepts: Black persons, neoplasms, and clinical trial recruitment. The search
resulted in 1,506 articles, of which 15 met inclusion criteria. Five main categories of recruitment and retention
strategies and interventions were identiﬁed based on their speciﬁc population focus and type of approach: (1)
participant identiﬁcation, (2) provider awareness/resources, (3) focused research staff interventions, (4) patient
and community–focused awareness strategies, and (5) participant-directed resources. Thirteen studies had
recruitment acceptance rates of over 30%. Eight studies with acceptance rates of $ 50% reported
implementing $ 5 strategies, with an average use of seven strategies across multiple categories. Five studies
with acceptance rates $ 50% implemented strategies in $ 3 categories. Four studies reported retention
rates $ 74%. Three studies with reported retention rates $ 74% used strategies in $ 3 categories, and all
included strategies aimed at meeting participant needs beyond the study. Our results show that many efforts that
aim to increase the recruitment and retention of Black participants into CCTs have great potential, but the most
promising strategies use a multiprong approach.
JCO Oncol Pract 00. © 2022 by American Society of Clinical Oncology
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Although innovations in cancer prevention, diagnosis,
and treatment decreased overall cancer-related mortality across the United States by 32% since 1991,1
racial and ethnic minorities still bear a disproportionate
number of negative cancer outcomes.2 Among Black
populations in the United States, lung, prostate,
multiple myeloma, and colorectal cancer have both
higher rates of incidence and mortality rates when
compared with non-Hispanic Whites.3 Complicating
these trends is the low recruitment and retention of
Black participants in cancer clinical trials (CCTs),4-6
which adversely affect the generalizability of promising
therapies to those with higher risk and poorer prognosis. Although considerable efforts have been made
to increase the diversity of CCT participants, only 10%
of study participants in National Cancer Institute (NCI)
trials are of a minority racial or ethnic background.7
Black people, who represent approximately 13% of the
US population, comprised only 3.1% of enrollees in

Federal Drug Administration Cancer Drug approval
requests and only 10.4% of CCT enrollees in 2016.8,9
Numerous patient, provider, and system-level barriers
to Black participation in CCTs have been reported.10-15
Commonly identiﬁed patient-level impediments to
successful recruitment of Black populations to CCTs
include individuals’ fear and mistrust of researchers
and medical institutions,16 religious beliefs,14 health
illiteracy,9,17-19 and limited awareness that studies may
be available or relevant to them.20,21 Social barriers
associated with participation in CCTs such as the cost
of cancer care, lost wages from time off work, securing
childcare, and managing travel burden have also been
implicated in patients’ inability to enroll in or continue
to participate in clinical trials.22,23
Patient decisions about enrollment in CCTs also depend on the ability of recruiters to communicate information about the trial or study clearly and effectively,
with an understanding of how patients’ values may
inﬂuence their decisions.24 Morgan et al identiﬁed
several behaviors among research coordinators, study

1

Downloaded from ascopubs.org by 165.225.62.13 on August 19, 2022 from 165.225.062.013
Copyright © 2022 American Society of Clinical Oncology. All rights reserved.

Arring et al

nurses, and professional recruiters that supported recruitment, such as establishing personal connections, demonstrating respect, expressing empathy, simplifying study
information, encouraging questions, equally discussing the
risks and beneﬁts of participation, maintaining ongoing
contact, and being ﬂexible.25,26 Eggly et al27 found that in the
setting of a positive patient-provider relationship, there was
a signiﬁcant positive association between oncologists’
recommendations and patients’ decisions to participate in
CCTs. Conversely, providers’ time constraints as well as
biased assumptions of patient disinterest or noncompliance
with CCT can thwart accrual of Black patients.6,28-31 Systemlevel barriers to CCT recruitment include health system
factors such as the lack of accessible clinics or facilities with
clinical trials and the overall limited availability of applicable
clinical trials for patients of color.32
Much of the treatment of cancers highly prevalent in Black
individuals continue to be based largely on outcomes from
clinical trials with fewer than 10% Black representation.
Hence, current treatments may be inadequate in Black
patients with these cancer diagnoses. Improving the enrollment and retention of Black participants in CCTs is
important not only to ensure the generalizability of trial
results but to improve patient responses to treatments that
may have long-term beneﬁts. Strategies aimed to improve
the successful recruitment and retention of Black participants in CCTs must address barriers across patient, provider, and system levels. To do so, however, it is imperative
to understand which strategies, interventions, or practices
have been implemented, at what level (patient, provider, or
system), and how and which work best. The objective of this
narrative scoping review, as part of a larger study aimed to
develop interventions to increase Black (inclusive of Black
patients from Caribbean, African American, and/or subSaharan African descent) patient participation in cancer
clinical trials, was to identify, describe, and categorize
strategies or interventions intended to improve the recruitment and retention of Black patients with breast, lung,
prostate, colorectal, or multiple myeloma cancer into CCTs
and the outcomes of these strategies or interventions on
accrual and retention rates.
METHODS
This narrative review was conducted using the Joanna
Briggs Institute approach for scoping reviews33 and the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis extension for Scoping Reviews criteria.34
Eligibility Criteria
Eligible studies included published projects (research
and/or quality) written in English that focused on Black
adults in the United States with breast, lung, prostate,
colorectal, or multiple myeloma cancer and that speciﬁcally reported strategies used for the recruitment
and/or retention of Black patients for a cancer clinical

trial and the recruitment and/or retention outcomes of
those strategies/interventions. Speciﬁc inclusion and
exclusion criteria are listed in Table 1.
Information Sources and Literature Search
A library informationist (KMS) performed comprehensive
searches of PubMed, Embase (Elsevier), Cochrane Library
(Wiley), PsycInfo (EBSCO), CINAHL (EBSCO), Scopus
(Elsevier), and Web of Science (SCI-EXPANDED, SSCI,
A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, and
CCR-EXPANDED) with members of the research team on
March 22, 2021. The searches were built around three
main concepts: Black persons, neoplasms, and clinical trial
recruitment. Major search terms for all databases were
represented by both controlled vocabulary and keywords
(Table 2). The resulting citations were imported into the
citation manager Endnote X9 (Clarivate Analytics) for
multipass duplicate detection and removal. Unique citation
records were uploaded to Covidence for screening.35 The
scoping review protocol was deposited in the University of
Michigan’s Institutional Repository, Deep Blue.36 All reproducible searches for all databases and associated
search ﬁles have also been deposited in Deep Blue.37
Study Selection
Articles were screened for eligibility in two phases. In phase I,
the title and abstract of every article was screened by two
of the three reviewers (N.M.A., B.L.B., or L.A.-P.) using the
inclusion and exclusion criteria. Eligibility differences were
reconciled through discussion. The same process was followed for the full-text review. Data from each study including general information, characteristics of included
studies, participants’ characteristics, recruitment and retention strategies, and outcome was extracted in Covidence by two authors (R.H. and A.H.). Any disagreements
were addressed by a third author (N.M.A.).
RESULTS
Our search, after removal of duplicates, resulted in 1,506
articles. Screening of abstracts and titles resulted in the
exclusion of 1,435 articles after applying inclusion and
exclusion criteria. An additional 56 articles were excluded
in the full-text review. The reasons for exclusion, in order of
frequency, were wrong patient population (20), abstract
only (13), wrong study design (11), wrong study outcomes
(eight), and wrong intervention (four). Our process resulted
with 15 articles that met all inclusion criteria (Fig 1).
Characteristics of Included Studies
Study characteristics are described categorically below by
trial type, trial timing, trial location, and participant characteristics and are summarized in Table 3.
Trial type. Most studies (11) recruited exclusively for
supportive care trials,38-42,45-47,50-52 which are studies that
treat symptoms or side effects from cancer or cancer
treatment. Three studies recruited exclusively for cancer
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TABLE 1. Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

Black adults in the United States
with breast, lung, prostate,
colorectal, or multiple myeloma
cancer
Speciﬁcally reports recruitment
and/or retention strategies for a
cancer clinical trial
Reports either retention and/or
recruitment outcomes of
strategies/interventions on the
Black population/community
Written in English
Conducted in the United States
May include research studies,
quality, and/or process
improvement projects

Written in languages other than English
Opinion pieces, editorials, and letters to
editor
Systematic or scoping reviews
Pediatric populations
Nonhuman subjects
Conducted outside of the United States

Studies imported for
screening (N = 1,522)

Duplicates removed (n = 16)

Studies screened (n = 1,506)

1,435 studies irrelevant

Studies excluded

Full-text studies assessed
for eligibility (n = 71)

(n = 56)

Wrong patient population (n = 20)
Abstract only
(n = 13)
(n = 11)
Wrong study design
(n = 8)
Wrong study outcomes
Wrong intervention
(n = 4)
(n = 0)
Studies ongoing
Studies awaiting classification (n = 0)

Studies included (n = 15)

FIG 1. PRISMA diagram.

treatment trials, which are studies that test interventions
(eg, drugs, approaches to surgery, and/or radiation therapy) as a treatment for cancer.43,48,49 One study recruited
for both supportive care and treatment trials.44
Trial timing. Nine studies exclusively recruited posttreatment cancer survivors (cancer survivor no longer receiving active cancer treatment).38-41,45,47,50-52 Four studies
exclusively recruited Black patients actively receiving
cancer treatment (eg, chemotherapy, radiation, and/or

TABLE 2. Example PubMed Search Strategies
1. "African Continental Ancestry Group"[Mesh] OR "African Americans"[Mesh]
OR "African Americans"[tw] OR "Africn American"[tw] OR black[tw] OR
blacks[tw]
2. "Breast Neoplasms"[Mesh] OR "Lung Neoplasms"[Mesh] OR "Colonic
Neoplasms"[Mesh] OR "Prostatic Neoplasms"[Mesh] OR "Multiple
Myeloma"[Mesh] OR ((sigmoid[tw] OR rectum[tw] OR rectal[tw] OR anal
[tw] OR anus[tw] OR colorectal[tw] OR Breast[tw] OR breasts[tw] OR
Mammary[tw] OR lung[tw] OR lungs[tw] OR Pulmonary[tw] OR colon[tw]
OR Colonic[tw] OR prostate[tw] OR Prostatic[tw] OR "multiple myeloma"[tw]
OR "Multiple Myelomas"[tw] OR Mesothelioma[tw] OR "myeloma
multiplex"[tw] OR myelomatosis[tw]) AND ("Neoplasms"[Mesh] OR
Neoplasia[tw] OR Neoplasias[tw] OR Neoplasm[tw] OR Tumors[tw] OR
Tumor[tw] OR Cancer[tw] OR Cancers[tw] OR Cancerous[tw] OR
Carcinoma[tw] OR Carcinomas[tw] OR oncology[tw] OR Sarcoma[tw] OR
carcinogenesis[tw] OR granuloma[tw] OR Adenoma[tw] OR oncology[tw]
OR oncologic[tw]))
3. "Community Participation"[Mesh] OR "Patient Dropouts"[Mesh] OR "Patient
Selection"[Mesh] OR "Patient Participation"[Mesh] OR "Refusal to
Participate"[Mesh] OR "Lost to Follow-Up"[Mesh] OR "Research
Subjects"[Mesh] OR "Clinical Trials as Topic"[Mesh] OR ((Trial[tw] OR trials
[tw] OR "Research Volunteers"[tw] OR "Research Subject"[tw] OR
"Research participants"[tw] OR "Health Sciences Research"[tw] OR
"Biomedical Research"[Mesh] OR "Biomedical Research"[tw] OR "medical
Research"[tw]OR "health Research"[tw] OR "cancer Research"[tw] OR
"oncology Research"[tw]) AND (Recruit[tw] OR recruited[tw] OR Recruits
[tw] OR recruitment[tw] OR enroll[tw] OR enrolled[tw] OR enrollment[tw]
OR enrolls[tw] OR retention[tw] OR attrition[tw] OR dropout[tw] OR
dropouts[tw] OR accrual[tw]))

surgery).43,44,48,49 Two studies included both posttreatment and active treatment cancer patients.42,46
Trial location. Studies were conducted around the United
States including Birmingham, AL (two),42,44 California (four
entire state38-41 and one Los Angeles48), Philadelphia, PA
(two),50,51 Columbia, SC (two),46,47 Washington, DC area
(two),49,52 Detroit, MI (one),43 and Chapel Hill, NC (one).45
Most (14 of 15) were conducted at NCI Comprehensive
Cancer Centers,38,40-52 and three studies included community cancer centers.42,46,48
Participant characteristics. The majority (14) of studies
included Black female patients with breast cancer, of which
12 included exclusively Black female patients with breast
cancer.38-46,48-52 Two studies included Black patients with
prostate cancer,44,47 two studies included Black patients
with lung cancer,42,44 and one study included Black patients with colorectal cancer.42 There were no studies including Black patients with multiple myeloma.
Strategies and Interventions
As detailed in Table 4, ﬁve categories of recruitment and retention strategies or interventions were identiﬁed for Black
patients with cancer on the basis of their speciﬁc audience and
type or focus of intervention: (1) participant identiﬁcation, (2)
provider awareness/resources, (3) focused research staff interventions, (4) patient and community–focused awareness
strategies, and (5) participant-directed resources. Participant
identiﬁcation strategies were used by 10 studies and included
using registry databases (six), physician referrals (six), and
clinic schedules (three) to locate and identify potential participants for clinical trials.38,39,41,42,44,47,49-51 Seven studies used
provider awareness/resource strategies to educate and
highlight the need for Black participant recruitment in CCTs;
these included letters to treating physicians (three) and
professional collaborations (two).38,41,44,46-48,50,53 Five studies used focused research staff interventions including
providing cultural competency training (three) and ensuring
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TABLE 3. Study Characteristics
Study
Ashing et al38

Location
CA

Type of Cancer Center Cancer Population
NCI

Ashing-Giwa et al39 CA

Active or PostTreatment

Study Design

Type of Trial Targeted

Breast

Post-treatment

Quasi-experimental (level II)

Supportive care

Breast

Post-treatment

Quasi-experimental (level II)

Supportive care

Behavioral Theory

Community Engaged
Approach

Ashing-Giwa and
Ganz40

CA

NCI

Breast

Post-treatment

Quasi-experimental (level II)

Supportive care

Ashing-Giwa and
Rosales41

CA

NCI

Breast

Post-treatment

Quasi-experimental (level II)

Supportive care

Dignan et al42

Birmingham, AL

Community Cancer
Center and NCI

Colorectal, lung, Active and postbreast
treatment

Quasi-experimental (level II)

Supportive care

Du et al43

Detroit, MI

NCI

Breast

Active treatment

Randomized control trial
(level I)

Cancer treatment

Fouad et al44

Birmingham, AL

NCI

Prostate, lung,
breast

Active treatment

Quasi-experimental (level II)

Supportive care and
cancer treatment

Germino et al45

Chapel Hill, NC

NCI

Breast

Post-treatment

Randomized control trial
(level I)

Supportive care

Heiney et al46

Columbia, SC

Community Cancer
Center and NCI

Breast

Active and posttreatment

Randomized control trial
(level I)

Supportive care

Heiney-Adams Recruitment Community advisory board
Model

Heiney et al47

Columbia, SC

NCI

Prostate

Post-treatment

Quasi-experimental mixed
methods (level II)

Supportive care

Heiney-Adams Recruitment Community partnerships
Model
with cancer and grassroots
organizations

Holmes et al48

Los Angeles, CA

Community Cancer
Center and NCI

Breast

Active treatment

Quality improvement (level
V)

Cancer treatment

Robinson et al49

Baltimore, MD;
Washington, DC

NCI

Breast

Active treatment

Quasi-experimental (level II)

Cancer treatment

Rogerino et al50

Philadelphia, PA

NCI

Breast

Post-treatment

Randomized control trial
(level I)

Supportive care

Established relationships
with religious
organizations and
attended community
events

Sturgeon et al51

Philadelphia, PA

NCI

Breast

Post-treatment

Randomized control trial
(level I)

Supportive care

Participated in community
events

Wallington et al52

Washington, DC

NCI

Breast

Post-treatment

Quasi-experimental mixed
methods (level II)

Supportive care

Used two community
advisory boards

Contextual model of HRQOL

Social Network Theory And
the Community Health
Advisors Network (CHAN)
Model

Theory of Planned Behavior

Abbreviations: AL, Alabama; CA, California; DC, District of Columbia; HRQOL, health-related quality of life; MD, Maryland; MI, Michigan; NC, North Carolina; NCI, National Cancer Institute; PA,
Pennsylvania; SC, South Carolina.
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Established relationships
with community and
religious organizations.
Attended community
events
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TABLE 4. Recruitment and Retention Strategies

Study

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates

Holmes et al48 51/59 (86%)

Population
Patients with breast
cancer
Active treatment

Cancer Clinical
Trial Type
Treatment

Participant
Identiﬁcation

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions

(continued on following page)
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Participant-Directed
Resources

Culturally sensitive CT Employed a nurse
brochures provided
navigator; to inform
in ofﬁces
patients about and
enroll eligible patients
in CTs; to facilitate
physician participation
in CTs; to coordinate
referrals to
investigators; and to
reduce community
physician trial-related
workload by providing
in-ofﬁce assistance
with patient screening,
treatment (when
appropriate), followup, and symptom
management
Nurse navigator met
participants needs
beyond the study
requirements ie,
transportation
assistance and
emotional support

Increasing Black Enrollment in Cancer Trials

Professional
collaborations
were established
with a private
surgical
oncologist, a
private breast
surgeon, a private
oncologist, and an
oncologist at an LA
county care facility
with the study
team
$300 USD grant
awarded to
physicians for
each patient
enrolled in at least
one CT, courtesy
of the Drew
Medical Society.
Medical
oncologists were
also offered $500
USD a month to
offset the nurse
navigators use of
ofﬁce space

Patient and
Community–Focused
Awareness Strategies

6 © 2022 by American Society of Clinical Oncology

TABLE 4. Recruitment and Retention Strategies (continued)

Study
Ashing-Giwa
and
Rosales41

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates
304/378 (80.4%)

Population

Cancer Clinical
Trial Type

Participant
Identiﬁcation

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions

Letters to treating
226/304 (74.5%) Patients with breast Supportive care Used California
cancer
population-based physicians
describing the
Post-treatment
cancer center
study and
registry, hospital
cancer registries, included a list of
potential
and community
participants
agencies

Patient and
Community–Focused
Awareness Strategies

Participant-Directed
Resources

(continued on following page)
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All participants received
Letters to potential
Staff cultural
reminder phone calls
participants in
competency
for forthcoming
English or Spanish
training
baseline
included a toll-free
Linguistically
number to call, also Letters addressed to
competent
participants were
included a
(Spanish
carefully crafted to be
personalized
speaking) CRAs
communicative,
welcome letter
were matched to
culturally sensitive,
participants on Up to seven phone
and brief. CRAs sent a
calls were made to
the basis of the
follow-up for any issue
potential
participants
or request sent to the
participants by
preferred
study team. CRAs met
linguistically
language
participant’s needs
matched CRA if no
beyond the study
response was
requirements by
received after 2responding to any
weeks
clinical-related
question from
participants and
provided participants
with appropriate
resources and
referrals including
community resources,
legal resources, social
services
Participants received a
$20 USD grocery card
and a $40 USD gift
card after completion
of the postbaseline
survey

JCO Oncology Practice

TABLE 4. Recruitment and Retention Strategies (continued)

Dignan et al42

143/194 (74%)

111/143 (77.6%) Patients with breast, Supportive care Used clinic
schedules to
colorectal,
approach
prostate, lung,
potential
hematologic, head
participants while
and neck, GI tract,
minimizing
gynecological,
disruption of
prostate cancer
workﬂow
Active and postClinic staff were
treatment
consulted
regarding the
eligibility of
patients
Treating physicians
in clinic-referred
potential
participants
New patients at the
clinic would not
be approached
so that the staff
did not attempt
recruitment
when they could
be receiving their
ﬁrst cancer
diagnosis

Ashing et al38

118/162 (73%)

88/162 (54%)

Population

Cancer Clinical
Trial Type

Participant
Identiﬁcation

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions

Patient and
Community–Focused
Awareness Strategies

Participant-Directed
Resources

Paid parking and $5
Consistent with the Participants were
called a maximum of USD for transportation
participant pool,
15 times to complete ($10 USD when gas
most study
prices rose
the baseline
recruiters were
dramatically in 2008).
assessment, if no
Black
response was noted Participants without
access to a car were
the research team
provided
would attempt to
transportation
reach out using
$15 USD for completing
other contact
each survey ($45 USD
methods
maximum)

Patients with breast Supportive care Patients identiﬁed Letters mailed to
treating physicians
cancer
using registry
described the
Post-treatment
databases and
study along with a
community
list of potential
agencies
Patients referred to patients for study
study by treating inclusion
physicians

(continued on following page)
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$20 USD grocery card
Recruitment letters
and a $40 USD gift
were mailed to all
card after completion
potential
of second assessment
participants
describing the study postbaselines
and instructed Black
cancer survivors to
call for more
information and
eligibility screening
Created recruitment
ﬂyers
Shared study
information packets
with potential
participants which
included study
instruments

Increasing Black Enrollment in Cancer Trials

Study

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates

8 © 2022 by American Society of Clinical Oncology

TABLE 4. Recruitment and Retention Strategies (continued)

Study

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates

Fouad et al44

272/378 (72%)

Population

Cancer Clinical
Trial Type

Participant
Identiﬁcation

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions

Hired research nurse
208/272 (74.5%) Patients with lung, Supportive care The program
manager
breast, prostate, Treatment
received the
cervical,
clinic schedule
lymphoma,
and identiﬁed
leukemia, head,
potential
and neck cancer
participants
Active treatment
Patients identiﬁed
through referrals
by nurses, social
workers, and
physicians
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Copyright © 2022 American Society of Clinical Oncology. All rights reserved.

Participant-Directed
Resources
Hired and trained two
individuals, who
matched the study’s
demographic proﬁle,
as lay patient
navigators. The
navigators were
trained in the study
protocol and the roles
of the study team. The
navigators attended
clinic visits for social
support and
communicated
regularly with
treatment team to
receive updates on
participants
Reminder phone calls for
appointments were
made by lay patient
navigators
Met participant needs by
creating individualized
plans with lay patient
navigators, linking
participants to
community resources,
and making ﬂexible
arrangements on the
basis of needs
Transportation and
lodging assistance
coordinated with lay
patient navigator

Arring et al

(continued on following page)

Patient and
Community–Focused
Awareness Strategies

JCO Oncology Practice

TABLE 4. Recruitment and Retention Strategies (continued)

Study

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates

Heiney et al46

88/133 (66%)

Population

Cancer Clinical
Trial Type

Patients with breast Supportive care
cancer
Active and posttreatment

Participant
Identiﬁcation

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions
Brochures were
mailed to Black
RNs in the state

Staff cultural
competency
training

9
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Participant-Directed
Resources

Thank you gifts (eg, gift
Letters to potential
card from a local store
participants
or small gift) after each
included a cover
letter from the PI, the assessment and
throughout the study
treating physician,
and the agency staff
Flyers/brochures
developed with the
help of community
advisory boards and
placed in clinics and
community events
Used participant
testimonials in
recruitment
materials
Book marks
PSAs on radio,
newspaper, and TV
outlets
Participated in health
fairs
Shared study
information packets
with potential
participants
Community
partnership/advisory
board used to
develop study
materials and to
build relationships
within the
community

Increasing Black Enrollment in Cancer Trials

(continued on following page)

Patient and
Community–Focused
Awareness Strategies
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TABLE 4. Recruitment and Retention Strategies (continued)

Study

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates

Population

Cancer Clinical
Trial Type

Participant
Identiﬁcation

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions

Patient and
Community–Focused
Awareness Strategies

Participant-Directed
Resources

Patients with breast Supportive care State registries used
cancer
to identify
Post-treatment
potential
participants

Letters mailed to invite
potential patients to
participate
Study website
designed and
maintained
Media
announcements in
print and
broadcasted
Research staff
attended
community events
and held 12
educational events
for Black survivors of
breast cancer

Rogerino et al50 112/223 (50%)

Patients with breast Supportive care Identiﬁed potential Professional
collaboration with
cancer
participants
Post-treatment
through state and YMCAs across
hospital registries Philadelphia
which acted as
intervention sites
and helped
disseminate
information about
the study

Invitation letters were Paid parking
mailed in waves and Participants received up
included paid return to $145 USD over the
postcards to indicate course of the year for
completing
interest or decline
measurement visits
Print and broadcast
media were
disseminated with
information about
the study
Information
disseminated in
churches, breast
cancer survivor
events, and support
groups

Ashing-Giwa
117/263 (44%)
and Ganz40

Patients with breast Supportive care Patients identiﬁed
cancer
by state registry
Post-treatment

Letters invited patients Half of the participants
to participate, which were given a $5 USD
gift card with the initial
included study
questionnaire and half
instrument
received the same $5
USD gift card after the
completion and return
of their survey

(continued on following page)

Downloaded from ascopubs.org by 165.225.62.13 on August 19, 2022 from 165.225.062.013
Copyright © 2022 American Society of Clinical Oncology. All rights reserved.

Arring et al

Sturgeon et al51 168/287 (59%)
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TABLE 4. Recruitment and Retention Strategies (continued)

Study

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates

Population

Cancer Clinical
Trial Type

Participant
Identiﬁcation

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions

Patient and
Community–Focused
Awareness Strategies

Participant-Directed
Resources

Patients with prostate Supportive care Physician referral Letters to treating
physicians
cancer
and databases
Post-treatment
used for subject
recruitment

Thank you notes when
Letters to potential
patient enrolled
participants
including postage
paid, response card
Posters created for
placement in clinics
and brochures
targeted at men
were given to
patients in clinics
Study website created
Used hospital
publications to
disseminate
recruitment
information
Community
partnerships with
cancer and
grassroots
organizations

Ashing-Giwa39 117/318 (37%)

Patients with breast Supportive care Potential
cancer
participants were
Post-treatment
identiﬁed from
the California
Tumor Registry
and participated
in an earlier study

$5 USD gift cards were
Two letters were
mailed to participants
mailed to potential
after completion of
participants—the
ﬁrst was an invitation surveys
letter from a PI they
had worked with
prior and the second
was from the current
PI
Study instrument
included in the
mailing

(continued on following page)
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Heiney, et al47 13/33 (39%)

12 © 2022 by American Society of Clinical Oncology

TABLE 4. Recruitment and Retention Strategies (continued)

Study

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates

Population

Cancer Clinical
Trial Type

Participant
Identiﬁcation
Patients identiﬁed
through a review
of electronic
health records
Patients identiﬁed
through clinic
schedules
Patients identiﬁed
through
physician referral
Patients identiﬁed
through clinician
referrals (eg,
nurse and social
worker)

Robinson
et al49

39/200 (19.5%)

Patients with breast
cancer
Active treatment

Treatment

Du et al43

4/89 (4.5%)

Patients with breast
cancer
Active treatment

Treatment

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions
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Participant-Directed
Resources

Shared 15-minute
culturally targeted
videos of Black
patients with cancer
to CTs

Phone calls to potential
participants
Created and shared an
18-minute video to
promote awareness
and knowledge
about clinical trials
to be watched at
home

Arring et al

(continued on following page)

Patient and
Community–Focused
Awareness Strategies

JCO Oncology Practice

TABLE 4. Recruitment and Retention Strategies (continued)

Study
Germino et al45,
a,b

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates
90/104 (87%)

Population

Cancer Clinical
Trial Type

Participant
Identiﬁcation

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions

Patients with breast, Supportive care
lung, and
colorectal cancer
Post-treatment

Patient and
Community–Focused
Awareness Strategies

Participant-Directed
Resources

(continued on following page)
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The study was
Whenever possible Brochures were
responsive to
developed with
Black recruiters
Black staff members participants needs:
were used to
to explain the study staff called during a
recruit Black
prescheduled time
in lay terms and
women
and in the evenings to
included photos of
avoid interrupting the
Black survivors
workday; the
Branded rubber balls
researchers used
with the study title
recruitment time to
and a toll-free
identify concerns (ie,
number were given
underinsurance) and
out at community
created resources
events
PSAs on radio stations guides for participants
and in newspapers/ Provided prepaid cell
phones for lowmagazines serving
income women
Black communities
Letters were mailed to Provided meals for
advocacy staff
Bishops who
contacted Pastors Gas cards were given to
Study packet included advocacy staff to travel
to training sessions
a study newsletter
Small gifts and thank you
featuring staff
and birthday cards
members to
sent throughout the
introduce the team
study and after
as real people
completion
committed to
helping BC survivors
Established
relationships with
community
organizations and
groups that
endorsed the
credibility of the
study to community
members
Staff members
attended
community events
such as cancer
walks, baseball
games, and support
groups

14 © 2022 by American Society of Clinical Oncology

TABLE 4. Recruitment and Retention Strategies (continued)

Study
Wallington
et al52,b,c

Black Patients With Black Patients
Cancer Acceptance
With Cancer
Rate
Retention Rates

Population

Cancer Clinical
Trial Type

Patients with breast Supportive care
cancer
Post-treatment

Participant
Identiﬁcation

Provider Awareness/ Focused Research
Resource Strategies Staff Interventions
Staff cultural
competency
training
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Participant-Directed
Resources

Used two community
advisory boards as
means of entry into
communities to
build capacity,
programming, and
support the study’s
goal of sustained
cultural competency
in CTs. Advisory
boards discuss the
needs of the
community and best
practices for
engaging
community
members

Arring et al

NOTE. Bold, . 50% acceptance rate; italics, 30% to 49% acceptance rate; bold and italics, , 30% acceptance rate.
Abbreviations: CRA, clinical research associate; CT, clinical trial; PI, principal investigator; PSA, Public Service Announcements; USD, US dollars.
a
Accrual increased by 373% after implementing the reported strategies.
b
Unable to calculate acceptance rate.
c
Three of six included studies met enrollment goals.

Patient and
Community–Focused
Awareness Strategies

Increasing Black Enrollment in Cancer Trials

racial and ethnic concordance between staff and participants (two).41,42,45,46,52 Fourteen studies used patient and
community–focused awareness strategies with letters to
potential participants (eight) and ﬂyers/brochures (ﬁve)
being implemented most often.38-43,45-47,49-51 Eleven studies
implemented participant-directed resource strategies with
participant incentives such as money or gift cards (seven)
and meeting participant needs beyond study requirements
(eg, linked participants to community resources and made
ﬂexible arrangements based on needs; four).38-42,44-47,50
Five studies used a behavioral theory including the Theory of Planned Behavior, Social Network Theory, and
Heiney-Adams Recruitment Model to frame their
interventions.41,44,46,47,49 Six studies reported the use of a
community-engaged research approach, which ranged
from having community members on the research team to
the use of community advisory boards.45-47,50-52 Ten studies
reported tailoring their strategies to ensure that they were
culturally and/or linguistically appropriate for their Black
population through a variety of tactics including focus
groups, community advisory boards, local residents as
members of the research team, using images of local
residents in campaigns, employing community members to
deliver the intervention, and using a professional social
media marketer to tailor content.38,41,44-48,50-52
Outcomes
We selected acceptance rate as one of our key outcomes.
Acceptance rate is deﬁned as the number of Black patients
with cancer who agreed to participate in a clinical trial
compared with the number of eligible Black patients with
cancer approached for recruitment. Acceptance rates were
calculated for each study that provided these details
(Table 4). Eight of the 15 studies had an acceptance
rate $ 50%.38,41,42,44,46,48,50,51 Three of the studies’ acceptance rates were between 30% and 49%.39,40,47 Two studies
had acceptance rates below 30%.43,49 Data to calculate
acceptance rates were not reported in two studies45,52;
however, Germino et al45 reported a 373% increase in accrual after implementing their strategies (Table 4).
All studies (eight) with an acceptance rate of $ 50% reported implementing ﬁve or more strategies, with an average
of seven strategies being used.38,41,42,44,46,48,50,51 The majority
(ﬁve) of the studies with acceptance rates $ 50% implemented strategies in three or more categories.38,41,42,44,46
Three of the seven studies with acceptance rates $ 50%
also reported using a behavioral theory to develop their
strategies.41,44,46 Four of the six studies that recruited patients during active cancer treatment into either supportive or
treatment clinical trials achieved an acceptance rate
of $ 50% using at least three different categories of
interventions.42,44,46,48 Two of the four studies recruiting into
cancer treatment trials achieved an acceptance rate
of $ 50% and used strategies in three intervention categories including the use of study navigators.44,48 Holmes
et al48 achieved the highest acceptance rate (86%) among

all the studies recruiting for cancer treatment trials by developing professional collaborations with community oncology providers, creating culturally appropriate recruitment
materials, and embedding a patient nurse navigator into the
community of focus and clinical practices. Both studies that
had an acceptance rate of , 30% were recruiting for cancer
treatment trials, used a video intervention for participants,
and reported using strategies in fewer than two intervention
categories.43,49
Of the ﬁve studies that reported retention rates as an
outcome, four reported retention rates $ 74% and one
reported a retention rate of 54%.38,41,42,44,45 Three of the
four studies that reported retention rates $ 74% used
strategies in three or more categories and all included
strategies aimed at meeting participant needs beyond the
study.41,44,45 For example, one study created resource
guides related to nonstudy topics for participants, and two
studies navigated participants to appropriate community
resources.41,44,45
Although no study conducted a formal cost analysis of their
intervention, four studies reported some associated cost
related to their recruitment and retention strategies.46-48,50
Chart review, physician referral, and state registry data sets
were identiﬁed as the most cost-effective strategies for
participant idenﬁcation.46,47,50 In one study, nurse navigation was determined to be cost effective at $5,677 US
dollars per patient because it reduced physician time
needed to recruit and complete follow-up and was found to
be half of the cost when compared with previous cancer
clinical trial cost estimates of $12,000 US dollars per
patient.48
DISCUSSION
In conclusion, facilitating the recruitment and retention of
Black participants into CCTs requires the development of
culturally competent strategies and interventions that address multilevel barriers14,16,54 and acknowledge historical
racism in research.32 Ten of the included studies speciﬁcally responded to the cultural, and linguistic, diversity
across Black communities by using images of local residents in campaigns and/or employing community members to deliver the intervention, which likely contributed to
their success.38,41,44-48,50-52 Involving communities in the
development of such strategies and interventions through
the use of focus groups, community advisory boards, and
the inclusion of community members as research partners
may also facilitate issues around the Black population’s
general lack of awareness of studies that may be available
or relevant to them, increase trust in the research overall,
improve the translation of ﬁndings into viable treatments
and therapies, and enhance health systems’ ability and
willingness to address institutional barriers.55,56
Our ﬁnding that most (13 of 15) of the studies in our sample
had acceptance rates over 30%, which is considerably

JCO Oncology Practice

15

Downloaded from ascopubs.org by 165.225.62.13 on August 19, 2022 from 165.225.062.013
Copyright © 2022 American Society of Clinical Oncology. All rights reserved.

Arring et al

higher than the national average of 10.4% for Black enrollment in CCTs, highlights that even minimal efforts to
increase the recruitment of Black participants into CCTs
may have positive results.9 However, this may reﬂect the
number of supportive care trials represented in our review.
Similar to previous studies, our results may also show that
increasing awareness of available and relevant studies
improved the enrollment and retention of Black patients
with cancer in CCTs.20,21
Combining approaches that engage key stakeholders along
the clinical trial trajectory—from community members, to
patients, to caregivers, and to cancer care providers—
however, seems to be most effective. Hamel et al57 posit
that community engagement strategies may help to overcome the barrier of medical mistrust. Furthermore, studies
that achieved an acceptance rate above 50% used an
average of seven interventions from at least three of our ﬁve
identiﬁed intervention categories while studies that used
only one or two interventions obtained lower than a 30%
acceptance rate. Our results support the recommendation
to use multilevel interventions to improve the racial and
ethnic diversity of participants in CCTs.57 Additionally, using
a behavioral theory to develop interventions may be a
promising strategy since three of the seven studies with
acceptance rates $ 50% reported using one to develop
their effective strategies.41,44,46 A more holistic approach to
recruiting and retaining Black participants in CCTs may
also yield a higher likelihood of acceptance. Engaging both
the treating providers and the community in recruitment
and retention efforts may have played a key role in the
success of the chosen strategies.
Patient navigation is also a potentially promising recruitment and retention intervention to recruit Black participants, who have historically low participation because of
the barriers and the emotional stress patients face related to
treatment decisions for a new and/or ongoing cancer diagnosis, for CCTs.58 The use of a research nurse navigator
had the highest acceptance rate (86%) overall although the
study was recruiting patients for cancer treatment trials.48
The patient lay navigator strategy was also used to retain
patients into both cancer treatment and supportive care
trials.44 Lay navigation demonstrated an acceptance rate of
72% and a retention rate of 74.5%.44 Both navigation
strategies were culturally tailored and provided participants
with supports beyond the study requirements, including
referrals to community services and providing emotional
support which appears to have helped to overcome the
additional treatment-related barriers.
One of the limitations of this review is that, as a scoping
review, it is exploratory in nature and, therefore, not
intended to be generalizable. In addition, given our research focus, most of the studies we initially identiﬁed did
not qualify for inclusion here, primarily because they did not
report speciﬁc recruitment and/or retention outcomes for
Black participants. Another limitation is that most studies in

our ﬁnal sample focused on the recruitment and retention
of Black female participants to breast cancer clinical trials.
Thus, the outcomes of strategies and interventions in our
sample may be more applicable to Black female breast
cancer survivors. In addition, most studies were in a
handful of states, were in urban settings, were carried out
by recognized NCI Comprehensive Cancer Centers, and
were recruiting for supportive care trials after cancer
treatment. We were also unable to tease out the differences
in effectiveness of strategies for African Americans as
compared with other Black populations or differences
between CCT types because of limited data. These ﬁndings
are similar to those by Loree et al8 who found that cancer
clinical trials rarely completed subanalyses for Black and
Hispanic participants. Detailed reporting and analysis are
needed to understand if an intervention is effective for
racially and ethnically diverse participants.
Although more may seem better in terms of cross-category
interventions, the costs associated with those efforts needs
to be clearly calculated and weighed against their outcomes. Cost-beneﬁt analysis may help identify which interventions are most effective for a given type of clinical trial,
particularly those comparing cancer treatment trials versus
supportive care trials. Determination of the overall costs of
strategies and interventions can facilitate a more accurate
allocation of resources and determine the sustainability of
ongoing recruitment and retention efforts.
Intervention strategies implemented to recruit more participants that fail to address and measure retention are only
partially successful. In our sample, only ﬁve of the 15 (33%)
studies reported retention rates. From our small sample,
addressing participant needs beyond the study is a
promising retention intervention. However, more research
is needed to understand this complex issue.
In summary, our results show that many efforts that aim to
increase the recruitment and retention of Black participants
into CCTs have great potential, but the most promising
strategies use a multiprong approach. Additionally, potentially successful interventions need to be replicated and
tested across different populations of Black patients with
cancer, need to include cost analyses for sustainability, and
accurately measure outcomes in terms of accrual and
retention.
Promising new models and frameworks that address the
complex trial processes and infrastructure challenges to the
recruitment and retention of more racially and ethnically
diverse participants in CCTs need to be tested across
patient and cancer types.59-61 Likewise, interventions used
in cancer research, as well as other types of research, that
help patients navigate through the social, economic, cultural, and structural complexities of the clinical trial
process20,62,63 need to be evaluated for their ability to increase CCT participant diversity.
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Increasing Black participation in CCTs, more speciﬁcally,
may be achievable if new approaches obtain buy-in from all
stakeholders: patients and their caregivers, the community,
health care providers, health care systems, and research
institutions. It is also important that new approaches incorporate culturally appropriate measures for each select
patient population, with deliberate consideration for cultural diversity across various Black communities. Documentation of what and how interventions work, along with
their associated costs, must consider both acceptance and
retention rates for any intervention that is used to increase
Black participation in clinical trials. Deepening our understanding of why and when Black patients with cancer

leave clinical trials is essential for the development of
multilevel and sustainable interventions aimed at increasing accrual of Black patients in CCTs. Engaging Black
patients with cancer in the design and conduct of recruitment and retention strategies, involving lay navigators
from the communities involved, providing supports that
extend beyond the study’s requirements, and ensuring that
the health care system addresses issues of institutional
racism, are all promising areas for increasing Black patients
with cancer inclusion in CCTs. Doing so may enhance
equitable treatments for Black patients with cancer and
improve overall cancer mortality among the US Black
population in the future.
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